Stocktoria
Indivior Pharmaceuticals, Inc. INDV
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2023-06-12
Indivior Pharmaceuticals, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Gross margin | 80.2% | 80.6% | 84.1% |
| Operating margin | 21.1% | 3.2% | -13.9% |
| Net margin | 16.9% | 0.6% | -11.5% |
| FCF margin | -7.5% | 0.6% | -28.2% |
| Return on assets | 17.5% | 0.5% | -7.2% |
| Return on equity | -214.3% | -2.1% | 68.5% |
| Debt / equity | -2.96× | -0.93× | -1.29× |
| Current ratio | 0.71 | 0.90 | 0.98 |
| Revenue growth | 4.3% | 8.7% | — |
Source: SEC EDGAR filings · CIK 0001625297 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.